<DOC>
	<DOCNO>NCT01710813</DOCNO>
	<brief_summary>To collect uniform meaningful data patient Pompe disease experience anaphylaxis , severe allergic reaction , and/or signal severe cutaneous and/or systemic immune complex-mediated reaction follow treatment alglucosidase alfa .</brief_summary>
	<brief_title>Alglucosidase Alfa Pompe Safety Sub-Registry</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Antigen-Antibody Complex</mesh_term>
	<criteria>The patient must enrol Pompe Registry ; Provide sign patient information authorization form ; Have confirm diagnosis Pompe disease ( confirmation diagnosis define documented GAA enzyme deficiency tissue source and/or documentation 2 GAA gene mutation ) ; Be na√Øve plan treat alglucosidase alfa prior enrollment , treat alglucosidase alfa . Patients exclude received investigational drug ( exclude alglucosidase alfa ) within 30 day prior sign Safety SubRegistry Patient Information Authorization form , take plan take investigational product enrol Safety SubRegistry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pompe disease</keyword>
	<keyword>alglucosidase alfa</keyword>
	<keyword>anaphylaxis</keyword>
	<keyword>severe cutaneous</keyword>
	<keyword>systemic immune complex-mediated reaction</keyword>
</DOC>